Novel Biomarkers for the Management of Chronic Hepatitis B Virus Infection

Kao, Jia‐Horng

doi:10.1007/978-981-16-3615-8_10

Search citation statements

Order By: Relevance

Paper Sections

Select...

Pros and Cons Of Expanding Treatment Indications In Patients...1

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2024

Publication Types

Select...

Article2

Relationship

Self Cite1

Independent1

Authors

Journals

Cited by 2 publications

(1 citation statement)

References 101 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Controversial issues regarding the treatment of chronic HBV infection include when to start anti-HBV therapy. [5,6] Solid evidence supports that patients with high serum HBV DNA liver ( ≥ 20,000 IU/mL for HBeAgpositive subjects and ≥ 2000 IU/mL for HBeAgnegative subjects) and active necroinflammatory activity of the liver (indicated by elevated serum alanine transaminase level ≥ 2 times upper limit of normal) should be considered for anti-HBV therapy. Patients with advanced fibrosis or established cirrhosis should also be given long-term anti-HBV therapy when their serum HBV DNA is detectable.…”

Section: Pros and Cons Of Expanding Treatment Indications In Patients...mentioning

confidence: 99%